Why the study?
Comparative analysis of flow-mediated dilation and vasoactive angiogenic and fibrogenic mediators between treatment-naive and treated systemic sclerosis patients was an unmet need.
Does vasodilator and immunosuppressive therapy improve endothelial dysfunction in patients with systemic sclerosis?
Population
SSc patients (n=24 treatment-naïve, n=10 vasodilator, n=22 vasodilator plus immunosuppressive) and 20 healthy controls
Comparison
Treatment-naïve vs vasodilator vs vasodilator plus immunosuppressive vs healthy controls
Key result
Flow-mediated vasodilation was significantly impaired in all systemic sclerosis patients compared to healthy controls (p<0.0001), with no significant improvement observed across different treatment regimens.
Authors
Loading...
Persistent endothelial dysfunction persists in SSc despite therapy; leaves open whether NO/ET-1 balance is a modifiable target.
Cross-Sectional (n=76)
Single-blind
No
Does vasodilator and immunosuppressive therapy improve endothelial dysfunction in patients with systemic sclerosis?
p-value: p=<0.0001
Endothelial dysfunction persists in systemic sclerosis patients despite vasodilator and immunosuppressive therapy, potentially driven by an unaltered NO/ET1 ratio.
Bhattacharjee et al. (2021) conducted a cross-sectional in Systemic Sclerosis (n=76). Vasodilator and/or immunosuppressive therapy vs. Treatment-naive SSc patients and healthy controls was evaluated on Flow-mediated vasodilation (FMD) (p=<0.0001). Flow-mediated vasodilation was significantly impaired in all systemic sclerosis patients compared to healthy controls (p<0.0001), with no significant improvement observed across different treatment regimens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: